WWTR1 and infantile convulsions and choreoathetosis: Therapeutic strategies aimed at reactivating the mechanisms limiting TAZ hyperactivation and/or inhibiting TAZ/YAP oncogenic effects might be highly beneficial for treating human iCCA.